Repligen (RGEN) Stock: Buy, Sell, or Hold?
RGEN - Repligen Corp
$181.70
4.47 (2.52%)
â˛
5d:
-4.21%
30d:
+5.07%
90d:
+28.45%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 27, 2026
24d
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RGEN is fairly priced but lacks strong directional signals. At 4.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RGEN is fairly priced but lacks strong directional signals. At 4.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$129.01
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$80.10
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $181.70, which is considered fair relative to its 30-day fair value range of $169.47 to $187.04. From a valuation perspective, the stock is trading at a premium (Forward PE: 68.6) compared to its historical average (59.9). At these levels, the market is pricing in 4.6% annual earnings growth.
Technical Outlook: Technically, RGEN is in a strong uptrend. Immediate support is located at $176.22, while resistance sits at $198.87.
Market Sentiment: RGEN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGEN is in a strong uptrend. Immediate support is located at $176.22, while resistance sits at $198.87.
Market Sentiment: RGEN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$169.47 -
$187.04
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
48.6%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($189.70)
- BULLISH: Expecting earnings turnaround to 4.6% growth with 11.9% revenue growth
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$169.47 -
$187.04
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$176.22
Resistance Level
$198.87
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
68.57
Wall Street Target
$189.70
(+4.4%)
Revenue Growth (YoY)
11.9%
Earnings Growth (YoY)
-65.9%
Profit Margin
5.3%
Valuation Premium vs History
+4.6% premium
PE vs Historical
68.6 vs 59.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.6%
(market-implied from PE analysis)
1-Year Target
$190.06
(+5%)
2-Year Target
$198.80
(+9%)
3-Year Target
$207.95
(+14%)
3-Yr Target (if PE normalizes)
(PE: 69â60)
PE COMPRESSION
$181.66
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 68.6, Growth: 28.4%)
$385.02
(+112%)
Base:
(SPY PE: 20.4, Growth: 28.4%)
$114.55
(-37%)
Bear:
(PE: 17.3, Growth: 28.4%)
$97.37
(-46%)
đ
Valuation based on Current Earnings
Forward PE: 67.11 | Forward EPS (Implied): $2.71
Bull Case
$219.40
(+21%)
Analyst growth 15.0%, PE expands to 70.5
Base Case
$181.70
(0%)
Market implied 0.0%, PE stable at 67.1
Bear Case
$139.00
(-24%)
Severe decline -15.0%, PE contracts to 60.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 6:19 PM ET
Data refreshes hourly during market hours. Next update: 7:19 PM
Data refreshes hourly during market hours. Next update: 7:19 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$84 | 53 HOLD |
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$476 | 35 SELL |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$66 | 67 BUY |
|
RMD
ResMed Inc |
BUY
19 analysts |
$250 | 61 BUY |
|
ALGN
Align Technology Inc |
BUY
18 analysts |
$206 | 65 BUY |
